Reliability, Validity, and Application of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) in Schizophrenic Patients Treated With Olanzapine Versus Haloperidol

Tunis, Sandra L.; Croghan, Thomas W.; Heilman, Douglas K.; Johnstone, Bryan M.; Obenchain, Robert L.

doi:10.1097/00005650-199907000-00008

Cited by 87 publications

(68 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…the PANSS). 71,[88][89][90] This may indicate that: (a) the generic HRQoL measures were only able to detect this component of HRQoL, or (b) depression is the only component of HRQoL within these groups of patients that is important within the context of HRQoL measurement. The issue is whether schizophrenia or anxiety has quality-of-life implications not adequately described by the five dimensions of the EQ-5D.…”

Section: Discussionmentioning

confidence: 99%

“…48, Six studies were undertaken internationally across more than one country. [66][67][68][69][70][71] The numbers of participants in the studies with schizophrenia or related conditions ranged from 15 to 2657. Participants included males and females with a mean age of participants with a schizophrenia spectrum disorder, reported in 21 of the 33 studies, ranging between 20.3 and 57.9 years.…”

Section: Schizophreniamentioning

confidence: 99%

“…Participants included males and females with a mean age of participants with a schizophrenia spectrum disorder, reported in 21 of the 33 studies, ranging between 20.3 and 57.9 years. 48,68,[70][71][72][73][75][76][77][78][79][80]82,84,86,[88][89][90][91]94,95 All studies obtained HRQoL information from patients; seven of these studies compared patient HRQoL values with published general population 'normative' values, [70][71][72][73][74][75][76] three compared HRQoL values with normal comparison participants that were recruited to the study [77][78][79] and two used 'norms' from healthy participants who had taken part in large surveys.…”

Section: Schizophreniamentioning

confidence: 99%

“…66,67,[69][70][71][72][73][74][75][76][77][78][79][80][81][82][83][84][85]88,[92][93][94][95] Although there appears to be strong evidence that the SF-36 is able to distinguish between general population norms and scores of people with schizophrenia (known-group validity), the evidence for convergent validity and responsiveness is less certain ( Table 4). Similar findings exist for the EQ-5D, with mixed evidence for the properties of convergent validity and responsiveness.…”

Section: Schizophreniamentioning

confidence: 99%

“…the Positive and Negative Syndrome Scale (PANSS)]. 71,[88][89][90] When testing associations between measures for convergent validity (or change scores in responsiveness), there are reasons to predict that stronger and more consistent correlations might exist between generic HRQoL measures and functioning [e.g. Global Assessment of Functioning (GAF), Social and Occupational Functioning Assessment Scale (SOFAS)] or mental health/schizophrenia-specific HRQoL [e.g.…”

Section: Schizophreniamentioning

confidence: 99%

See 4 more Smart Citations

A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures

Brazier

Connell

Papaioannou

et al. 2014

Health Technology Assessment

207

187

View full text Add to dashboard Cite

This report should be referenced as follows:Brazier J, Connell J, Papaioannou D, Mukuria C, Mulhern B, Peasgood T, et al. A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technol Assess 2014;18(34). This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/). Health Technology Assessment is indexed and abstracted inEditorial contact: nihredit@southampton.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme or, commissioned/managed through the Methodology research programme (MRP), and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions. To strengthen the evidence base for health research, the MRP oversees and implements the evolving strategy for high quality methodological research. In addition to the MRC and NIHR funding partners, the MRP takes into account the needs of other stakeholders including the devolved administrations, industry R&D, and regulatory/advisory agencies and other public bodies. The MRP funds investigator-led and needsled research proposals from across the UK. In addition to the standard MRC and RCUK terms and conditions, projects commissioned/managed by the MRP are expected to provide a detailed report on the research findings and may publish the findings in the HTA journal, if supported by NIHR funds.The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy o...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Schizophreniamentioning

confidence: 99%

Section: Schizophreniamentioning

confidence: 99%

Section: Schizophreniamentioning

confidence: 99%

Section: Schizophreniamentioning

confidence: 99%

See 3 more Smart Citations

A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures

Brazier

Connell

Papaioannou

et al. 2014

Health Technology Assessment

207

187

View full text Add to dashboard Cite

show abstract

Effect of Antipsychotic Medication Alone vs Combined With Psychosocial Intervention on Outcomes of Early-Stage Schizophrenia

Guo¹,

Zhai²,

Liu³

et al. 2010

Arch Gen Psychiatry

126

107

View full text Add to dashboard Cite

Context Antipsychotic drugs are limited in their ability to improve the overall outcome of schizophrenia. Adding psychosocial treatment may produce greater improvement in functional outcome than does medication treatment alone. Objective To evaluate the effectiveness of antipsychotic medication alone versus combined with psychosocial intervention on outcomes of early stage schizophrenia. Design, Setting, and Participants Randomized controlled trial of a clinical sample of 1268 patients with early stage schizophrenia, conducted at 10 clinical sites in China from 2005–2007. Intervention Patients were randomly assigned to antipsychotic medication treatment only or antipsychotic medication plus 12 months of psychosocial intervention, consisting of psycho-education, family intervention, skills training and cognitive-behavioral therapy, administered over 48 group sessions. Main Outcome Measures The rate of treatment discontinuation or change due to any cause, relapse or remission, and assessments of insight, treatment adherence, quality of life and social functioning. Results The rates of treatment discontinuation or change due to any cause were 32.8% in the combined treatment group and 46.8% in the medication alone group. Comparisons with medication treatment alone showed lower risk for any cause discontinuation with combined treatment (hazard ratios [HR], 0.62; 95% confidence interval [CI], 0.52–0.74; p<0.001); and lower risk for relapse with combined treatment (HR, 0.57; 95%CI, 0.44–0.74; p<0.001). The combined treatment group exhibited greater improvement in insight (p<0.001), social functioning (p=0.002), activities of daily living (p<0.001), and in 4 domains of quality of life as measured by Medical Outcome Study Short-Form 36-item questionnaire (all p-values<0.02). Furthermore, a significantly higher proportion of patients receiving combined treatment obtained employment or accessed education (p=0.001). Conclusions Compared to those receiving medications only, early stage schizophrenia patients receiving medications and psychosocial intervention had a lower rate of treatment discontinuation or change, lower risk of relapse, and improved insight, quality of life and social functioning.

show abstract

Burden of Medical Illness in Women With Depression and Posttraumatic Stress Disorder

Frayne

Seaver²,

Loveland³

et al. 2004

Arch Intern Med

117

View full text Add to dashboard Cite

show abstract

Reliability, Validity, and Application of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) in Schizophrenic Patients Treated With Olanzapine Versus Haloperidol

Abstract: The SF-36 can be a reliable and valid measure of perceived functioning and well being for schizophrenic patients. The perceptions of functioning can be valuable indices of disease burden and can help to demonstrate the effectiveness of newer antipsychotic medications such as olanzapine.

Cited by 87 publications

References 39 publications

A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures

A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures

Effect of Antipsychotic Medication Alone vs Combined With Psychosocial Intervention on Outcomes of Early-Stage Schizophrenia

Burden of Medical Illness in Women With Depression and Posttraumatic Stress Disorder

Contact Info

Product

Resources

About